Posted by Michael Wonder on 27 Jul 2022
GSK announces US FDA approval of Benlysta (belimumab) for paediatric patients with active lupus nephritis
27 July 2022 - Benlysta is now the first and only biologic approved for adults and children who have lupus or lupus nephritis
GSK today announced that the US FDA has approved Benlysta (belimumab) for the treatment of children aged 5 to 17 with active lupus nephritis who are receiving standard therapy.
